Sugi Predict

Sugi Predict / Compounds / SCHEMBL709793

SCHEMBL709793

SCHEMBL709793

O=C(O)C1CCC(O)(C(F)(F)F)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2C19 P33261 3/20 0.39
▸ LMNA P02545 3/20 0.39
▸ GRM2 Q14416 2/20 0.39
▸ GRM3 Q14832 2/20 0.39
▸ GRM4 Q14833 2/20 0.39
▸ TSHR P16473 2/20 0.39
▸ CYP1A2 P05177 2/20 0.39
▸ ALOX15 P16050 2/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ GRM8 O00222 1/20 0.39
▸ GRM6 O15303 1/20 0.39
▸ GRM5 P41594 1/20 0.39
▸ MTOR P42345 1/20 0.39
▸ GRM1 Q13255 1/20 0.39
▸ PLCB1 Q9NQ66 1/20 0.39
▸ GABRP O00591 1/20 0.38
▸ GABRD O14764 1/20 0.38
▸ GABRA1 P14867 1/20 0.38
▸ GABRB1 P18505 1/20 0.38
▸ GABRG2 P18507 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16336444 1.00 CYP2C19 (0.39) CYP2C19LMNAGRM2GRM3GRM4
SCHEMBL22348346 1.00 CYP2C19 (0.39) CYP2C19LMNAGRM2GRM3GRM4
SCHEMBL15684228 0.88 CYP2C19 (0.46) CYP2C19LMNAGRM2GRM3GRM4
SCHEMBL30298830 0.81 PDK2 (0.36) CYP2C19LMNAGRM2GRM3GRM4
SCHEMBL26631347 0.77 CYP2C19 (0.50) CYP2C19LMNAGRM2GRM3GRM4
SCHEMBL710044 0.77 CYP2C19 (0.50) CYP2C19LMNAGRM2GRM3GRM4
SCHEMBL31214195 0.76 CYP1A2 (0.39) CYP2C19LMNAGRM2GRM3GRM4
Hydrochloric Acid SCHEMBL27035460 0.75 GRM2 (0.46) CYP2C19LMNAGRM2GRM3GRM4
SCHEMBL12971036 0.74 TSHR (0.46) CYP2C19LMNAGRM2GRM3GRM4
SCHEMBL26906347 0.74 TSHR (0.33) TSHRHSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12606541-B2 PPARg modulators and methods of use EISAI R&D MANAGEMENT CO., LTD. (JP) 2026-04-21 — — US disclosed
US-20260022116-A1 IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF SANOFI-AVENTIS RECHERCHE & DÉVELOPPEMENT (FR) 2026-01-22 — — US disclosed
EP-4558500-A1 IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF Sanofi (FR) 2025-05-28 — — EP disclosed
US-12227496-B2 Substituted bicyclic compounds as farnesoid X receptor modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2025-02-18 — — US disclosed
WO-2024017977-A1 IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF SANOFI (FR) 2024-01-25 — — WO disclosed
EP-4240736-A1 PPAR GAMMA MODULATORS AND METHODS OF USE Eisai R&D Management Co., Ltd. (JP) 2023-09-13 — — EP disclosed
CN-116635380-A PPARgamma modulators and methods of use 卫材R&D管理有限公司 2023-08-22 — — CN disclosed
US-20230109670-A9 SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS BRISTOL MYERS SQUIBB CO (US) 2023-04-06 — — US disclosed
CN-111479813-B Triazolobenzazepines as vasopressin V1A receptor antagonists 吉瑞工厂 2023-03-21 — — CN disclosed
US-20230062861-A1 PPARg MODULATORS AND METHODS OF USE EISAI R&D MANAGEMENT CO., LTD. (JP) 2023-03-02 — — US disclosed
EP-2970200-A1 PYRIDINE CDK9 KINASE INHIBITORS Abbvie Inc. (US) 2016-01-20 — — EP disclosed
US-20150005279-A1 PRIMARY CARBOXAMIDES AS BTK INHIBITORS ABBVIE INC. (US) 2015-01-01 — — US disclosed
US-20150005279-A1 PRIMARY CARBOXAMIDES AS BTK INHIBITORS ABBVIE INC. (US) 2015-01-01 — — US disclosed
US-20150005279-A1 PRIMARY CARBOXAMIDES AS BTK INHIBITORS ABBVIE INC. (US) 2015-01-01 — — US disclosed
WO-2014210255-A1 PRIMARY CARBOXAMIDES AS BTK INHIBITORS ABBVIE INC. (US) 2014-12-31 — — WO disclosed
WO-2014179564-A1 THIAZALOPYRROLIDINE INHIBITORS OF ROR-GAMMA VITAE PHARMACEUTICALS, INC. (US) 2014-11-06 — — WO disclosed
WO-2014160017-A1 PYRIDINE CDK9 KINASE INHIBITORS ABBVIE INC. (US) 2014-10-02 — — WO disclosed
US-20140275011-A1 PYRIDINE CDK9 KINASE INHIBITORS ABBVIE INC. (US) 2014-09-18 — — US disclosed
US-8124613-B2 Spirotropane compounds VIROCHEM PHARMA INC. (CA) 2012-02-28 — — US disclosed
US-20110105546-A1 SPIROTROPANE COMPOUNDS VIROCHEM PHARMA INC. (CA) 2011-05-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12227496-B2 Substituted bicyclic compounds as farnesoid X receptor modulators FXR1, NR1H4, FXR2 CYP2C19 1139/4885LMNA 3646/4885GRM2 1024/4885
US-20230109670-A9 SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS FXR1, NR1H4, FXR2 CYP2C19 1139/4885LMNA 3646/4885GRM2 1024/4885
US-20150005279-A1 PRIMARY CARBOXAMIDES AS BTK INHIBITORS BTK, SYK, MYD88 CYP2C19 305/4885LMNA 2950/4885GRM2 3304/4885
US-20140275011-A1 PYRIDINE CDK9 KINASE INHIBITORS CDK9, CDK19, CDK6 CYP2C19 362/4885LMNA 2427/4885GRM2 2252/4885
US-20230062861-A1 PPARg MODULATORS AND METHODS OF USE PPARG, PPARA, PPARD CYP2C19 169/4885LMNA 3332/4885GRM2 919/4885
US-12606541-B2 PPARg modulators and methods of use PPARG, PPARA, PPARD CYP2C19 350/4885LMNA 1537/4885GRM2 368/4885
US-20260022116-A1 IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF MAPK1, MAPK3, MAPK6 CYP2C19 2599/4885LMNA 3239/4885GRM2 1651/4885
US-20110105546-A1 SPIROTROPANE COMPOUNDS CCR5, CXCR1, CXCR2 CYP2C19 1030/4885LMNA 2735/4885GRM2 1798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.